Caplin Point Laboratories Limited (CAPLIPOINT.NS)
INR 1967.1
(-0.24%)
INR 1967.1
(-0.24%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.5 Billion INR | 23.38% |
| 2022 | 2.84 Billion INR | 25.48% |
| 2021 | 2.26 Billion INR | 41.31% |
| 2020 | 1.6 Billion INR | -5.28% |
| 2019 | 1.69 Billion INR | 54.46% |
| 2018 | 1.09 Billion INR | -19.77% |
| 2017 | 1.36 Billion INR | 2.06% |
| 2016 | 1.33 Billion INR | 1.79% |
| 2015 | 1.31 Billion INR | -2.92% |
| 2014 | 1.35 Billion INR | 14.72% |
| 2013 | 1.17 Billion INR | 28.72% |
| 2012 | 916.66 Million INR | 24.74% |
| 2011 | 734.86 Million INR | 63.33% |
| 2010 | 449.91 Million INR | 28.29% |
| 2009 | 350.69 Million INR | -6.38% |
| 2008 | 374.59 Million INR | 9.54% |
| 2007 | 341.96 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -23.46 Billion INR | -769.45% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 3.5 Billion INR | 0.0% |
| 2023 Q2 | 3.1 Billion INR | 0.0% |
| 2023 FY | 3.5 Billion INR | 23.38% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 3.07 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 2.84 Billion INR | 0.0% |
| 2022 FY | 2.84 Billion INR | 25.48% |
| 2021 Q2 | 2.17 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 2.26 Billion INR | 0.0% |
| 2021 FY | 2.26 Billion INR | 41.31% |
| 2020 FY | 1.6 Billion INR | -5.28% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 2.03 Billion INR | 0.0% |
| 2020 Q4 | 1.6 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 1.49 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q4 | 1.69 Billion INR | 0.0% |
| 2019 FY | 1.69 Billion INR | 54.46% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q4 | 1.09 Billion INR | 0.0% |
| 2018 FY | 1.09 Billion INR | -19.77% |
| 2018 Q2 | 1.54 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q4 | 1.36 Billion INR | 0.0% |
| 2017 FY | 1.36 Billion INR | 2.06% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 1.2 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 FY | 1.33 Billion INR | 1.79% |
| 2016 Q4 | 1.33 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 1.22 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 FY | 1.31 Billion INR | -2.92% |
| 2015 Q1 | 1.35 Billion INR | 0.0% |
| 2015 Q2 | 1.22 Billion INR | -9.35% |
| 2015 Q3 | 1.22 Billion INR | 0.0% |
| 2015 Q4 | 1.31 Billion INR | 7.1% |
| 2014 Q4 | - INR | -100.0% |
| 2014 FY | 1.35 Billion INR | 14.72% |
| 2014 Q1 | 1.17 Billion INR | 0.0% |
| 2014 Q2 | - INR | -100.0% |
| 2014 Q3 | 1.34 Billion INR | 0.0% |
| 2013 Q1 | 916.66 Million INR | 0.0% |
| 2013 Q4 | - INR | -100.0% |
| 2013 FY | 1.17 Billion INR | 28.72% |
| 2013 Q3 | 1.08 Billion INR | 0.0% |
| 2013 Q2 | - INR | -100.0% |
| 2012 Q3 | 712.51 Million INR | 0.0% |
| 2012 Q1 | 734.86 Million INR | 0.0% |
| 2012 FY | 916.66 Million INR | 24.74% |
| 2012 Q4 | - INR | -100.0% |
| 2011 FY | 734.86 Million INR | 63.33% |
| 2010 FY | 449.91 Million INR | 28.29% |
| 2009 FY | 350.69 Million INR | -6.38% |
| 2008 FY | 374.59 Million INR | 9.54% |
| 2007 FY | 341.96 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Hester Biosciences Limited | 3.59 Billion INR | 2.479% |
| Albert David Limited | 1.15 Billion INR | -204.807% |
| Alembic Limited | 1.43 Billion INR | -144.787% |
| Alkem Laboratories Limited | 48.6 Billion INR | 92.788% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 78.459% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -437.439% |
| Bajaj HealthCare Limited | 4.86 Billion INR | 27.982% |
| FDC Limited | 3.7 Billion INR | 5.489% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | 32.336% |
| Gufic Biosciences Limited | 5.59 Billion INR | 37.398% |
| Hikal Limited | 12.99 Billion INR | 73.023% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -53.119% |
| Ind-Swift Limited | 13.45 Billion INR | 73.942% |
| Innova Captab Limited | 4.89 Billion INR | 28.455% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -1081.291% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 94.279% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -444.447% |
| Laurus Labs Limited | 42.71 Billion INR | 91.793% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -226.24% |
| Lupin Limited | 96.23 Billion INR | 96.357% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -77.381% |
| Medico Remedies Limited | 438.24 Million INR | -699.92% |
| Morepen Laboratories Limited | 4.45 Billion INR | 21.395% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 68.75% |
| Orchid Pharma Limited | 3.84 Billion INR | 8.805% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -36.873% |
| RPG Life Sciences Limited | 1.38 Billion INR | -153.992% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | 75.123% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 98.09% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -72.331% |
| Themis Medicare Limited | 1.88 Billion INR | -85.726% |
| Unichem Laboratories Limited | 8.06 Billion INR | 56.556% |
| Vaishali Pharma Limited | 371.16 Million INR | -844.491% |
| Venus Remedies Limited | 1.39 Billion INR | -151.694% |
| Wanbury Limited | 3.15 Billion INR | -11.094% |
| Windlas Biotech Limited | 1.76 Billion INR | -98.877% |
| ZIM Laboratories Limited | 2.08 Billion INR | -68.477% |
| Ipca Laboratories Limited | 33.74 Billion INR | 89.611% |
| Aarti Drugs Limited | 11.5 Billion INR | 69.527% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 57.511% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -1113.855% |
| Brooks Laboratories Limited | 248.6 Million INR | -1310.131% |
| Eris Lifesciences Limited | 38.26 Billion INR | 90.839% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 44.61% |
| Sigachi Industries Limited | 2.53 Billion INR | -38.492% |
| Sakar Healthcare Limited | 1.26 Billion INR | -177.5% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 97.697% |
| Divi's Laboratories Limited | 18.99 Billion INR | 81.54% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | 4.248% |
| Mankind Pharma Limited | 23.87 Billion INR | 85.317% |
| Sequent Scientific Limited | 8.27 Billion INR | 57.632% |
| Neuland Laboratories Limited | 5.49 Billion INR | 36.245% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 67.262% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 94.616% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 95.117% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -347.243% |
| Wockhardt Limited | 39.87 Billion INR | 91.207% |
| Bal Pharma Limited | 2.51 Billion INR | -39.594% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 96.723% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -66.233% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -2093.866% |
| Shilpa Medicare Limited | 12.93 Billion INR | 72.893% |
| Valiant Laboratories Limited | 1.05 Billion INR | -231.26% |
| Ajanta Pharma Limited | 10.71 Billion INR | 67.269% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -103.555% |
| Granules India Limited | 22.95 Billion INR | 84.728% |
| Medicamen Biotech Limited | 940.36 Million INR | -272.791% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -200.855% |
| Piramal Enterprises Limited | 560.47 Billion INR | 99.375% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 95.727% |
| NATCO Pharma Limited | 10.53 Billion INR | 66.715% |
| Suven Life Sciences Limited | 148.62 Million INR | -2258.751% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -17.878% |
| Strides Pharma Science Limited | 37.68 Billion INR | 90.697% |
| Indoco Remedies Limited | 10.34 Billion INR | 66.104% |
| Alpa Laboratories Limited | 307.12 Million INR | -1041.436% |
| Lasa Supergenerics Limited | 541.92 Million INR | -546.879% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 9.949% |